Man, time flies. I can't believe almost a year has passed since the incident at ICAD. That's the big Alzheimer's Disease scientific research conference that was held in Chicago in late July last year. This year, it's in Vienna and it's going on right now. I've never been to Austria. I wish, not just for all of the desperate patients and their caretakers, that I had a compelling reason to have made the case to CNBC management that a trip to Vienna was in order. But there unfortunately aren't any major, potentially clinical-practice changing or stock-moving drug test results coming out at this year's conference.
We went last year because Wyeth and Elan were presenting the findings of their highly anticipated mid-stage study on the experimental Alzheimer's drug known as Bap, for short. It's a big reason why Pfizer is buying Wyeth and why Johnson & Johnson just did a deal with Elan.